Pharming Group/$PHAR
1D1W1MYTD1Y5YMAX
Capital at risk
About Pharming Group
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
- Ticker
- $PHAR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 407
- Headquarters
- Leiden, Netherlands
- Website
- www.pharming.com
Pharming Group Metrics
BasicAdvanced
$705M
786.25
$0.01
0.07
-
Price and volume
Market cap
$705M
Beta
0.07
52-week high
$21.34
52-week low
$9.62
Average daily volume
30K
Financial strength
Current ratio
3.01
Quick ratio
2.309
Long term debt to equity
0.385
Total debt to equity
0.419
Interest coverage (TTM)
2.31%
Profitability
EBITDA (TTM)
32.879
Gross margin (TTM)
86.52%
Net profit margin (TTM)
2.54%
Operating margin (TTM)
6.92%
Effective tax rate (TTM)
41.29%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
3.47%
Return on equity (TTM)
3.65%
Valuation
Price to earnings (TTM)
786.25
Price to revenue (TTM)
19.076
Price to book
2.32
Price to tangible book (TTM)
4.4
Price to free cash flow (TTM)
203.418
Free cash flow yield (TTM)
0.49%
Free cash flow per share (TTM)
0.049
Growth
Revenue change (TTM)
7.84%
Earnings per share change (TTM)
-196.85%
3-year revenue growth (CAGR)
21.11%
10-year revenue growth (CAGR)
40.28%
3-year earnings per share growth (CAGR)
-21.70%
10-year earnings per share growth (CAGR)
-9.79%
What the Analysts think about Pharming Group
Analyst ratings (Buy, Hold, Sell) for Pharming Group stock.
Analyst projections of the future price of Pharming Group stock.
Bulls say / Bears say
Joenja revenue rose 40% year on year to US$17.9 million in the second quarter, while new patient enrolments and prescriber additions improved. This gives Pharming a growing product to offset pressure on its older franchise. (Pharming)
Joenja is expanding geographically and by age group: the EU authorised it in May, Japan launched it in August, and the US approved treatment for eligible four-to-11-year-olds in September. These launches widen the commercial base without requiring a new drug discovery programme. (Pharming, Pharming)
Early Phase II data support testing leniolisib beyond APDS: the 13-patient study reported clinical improvements, including a mean 26.4% reduction in spleen volume, with no new safety signals. A successful CVID readout could open a substantially larger patient population than the current indication. (PHAR SEC Filing)
RUCONEST revenue fell 10% year on year in the second quarter and 12% in the first half, leading Pharming to cut 2026 revenue guidance by US$30 million to US$375–395 million. The larger RUCONEST franchise still generated roughly four times Joenja’s quarterly revenue, so Joenja’s faster growth has not yet offset the decline. (Pharming, Insider Monkey)
Cash used in operations was US$7.7 million in the first half, versus cash generated in the prior-year period, while cash and marketable securities fell to US$159.5 million. Pharming is also investing more than US$40 million in additional research and development, which could increase funding pressure if sales do not recover. (Pharming)
The broader leniolisib opportunity remains clinically unproven: the positive genetic-PID study was single-arm and involved only 13 patients, while the separate CVID results are still pending. A small early study may not translate into regulatory approval, durable efficacy or commercial uptake in the larger population. (PHAR SEC Filing, Pharming)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Pharming Group Financial Performance
Revenues and expenses
Pharming Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Pharming Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.